BellRing Brands

BRBR

Market cap $1.41B

BellRing Brands (BRBR) closed at $12.48 in the latest trading session, marking a +2.72% move from the prior day.

A prominent researcher named the stock its bear of the day for Thursday. It pointed out that the company is struggling on several fronts.

ST. LOUIS, July 08, 2026 (GLOBE NEWSWIRE) -- BellRing Brands, Inc. (NYSE:BRBR) today announced it will release its financial results for the third quarter of fiscal year 2026 and its fiscal year 2026 outlook on August 4, 2026, at 7:00 a.m. ET. The release will be followed by a conference call at 8:30 a.m. ET to discuss the results and outlook. Michael C. Axelrod, announced today as the Company's next President and Chief Executive Officer effective July 29, 2026, and Paul A. Rode, Chief Financial Officer, will participate in the call.

ST. LOUIS, July 08, 2026 (GLOBE NEWSWIRE) -- BellRing Brands, Inc. (NYSE:BRBR) (“BellRing”) today announced that Michael Axelrod has been appointed as the company's next President and Chief Executive Officer, effective July 29, 2026. He will also be appointed to the Company's Board of Directors. Darcy Davenport, who announced her intention to retire from the Company earlier this year, will serve in a senior advisory capacity to support a seamless leadership transition and provide strategic support.

Gen-Z consumers frequently hear the well-meaning, but perhaps oversimplified advice to quit paying $8 dollars for their morning coffee. But human nature has a way of adapting.

The latest trading day saw BellRing Brands (BRBR) settling at $11.55, representing a +1.4% change from its previous close.

In the most recent trading session, BellRing Brands (BRBR) closed at $8.81, indicating a -1.12% shift from the previous trading day.

It will soon no longer be a component of the S&P 400 MidCap index. Investors should be aware that this will have little to no effect on its fundamentals.

Wells Fargo's chief agriculture economist Dr. Michael Swanson told Bloomberg Businessweek on May 29 that GLP-1 weight-loss drugs (Ozempic, Wegovy, Mounjaro, Zepbound) will eventually match statins at roughly 90 million prescriptions, calling the trend “here to stay” because it's prescribed, not faddish.

BellRing Brands (NYSE:BRBR) on Tuesday reported worse-than-expected second-quarter financial results and cut its FY26 sales guidance below estimates.